Vibration TherapyPhase 4NCT07921810
Improving Morning Strength and Cognitive Performance Using Caffeine or Whole-body Vibration.
A Phase 4 study testing Caffeine (300mg) and whole-body vibration in people with Vibration Therapy and Caffeine, run by Liverpool John Moores University at 1 site in United Kingdom.
Trial summary
Improving morning strength and cognitive performance using caffeine or whole-body vibration. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Vibration Therapy, Caffeine, Control Condition
- What is being tested?
- Caffeine (300mg) and whole-body vibration
- Type of treatment
- Pill or oral medicine, Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Nov 2026to 1 Mar 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 18-35years old
- Healthy (as determined by the pre-participation questionnaire)
- >2 years strength trained individuals
- Consume >150 mg/day of caffeine
- Be able to stick to the retiring and waking schedule of the study as well as no exercise 24 h before and no caffeine.
Who cannot join
- Age: <18 or >35 years old
- Consume <150 mg/day of caffeine
- Deemed unhealthy/unable to perform exercise determined by PAR-Q
- Shift worker or having travelled out of the UK time zone within the last month of testing
- Muscle related injury or broken/fractured bone within the past 3 years Diagnosed sleep disorder
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Tom Reilly Building
Liverpool, Merseyside, L3 3AF
Joao Agulhari, BSc, 07379664724, jpagulhari@gmail.com
About this study
Improving morning strength and cognitive performance using caffeine or whole-body vibration.
- Conditions
- Vibration Therapy, Caffeine, Control Condition, Placebo - Control
- Being tested
- Caffeine (300mg), whole-body vibration, Placebo, Control
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Caffeine (300mg)Drug
Caffeine (300mg; 3x 100mg)
whole-body vibrationDevice
15 min of WBV at 60 Hz
PlaceboDietary supplement
1.6 mg Maltodextrin
ControlBehavioural
no-pill control
| Study group | Role | What they receive |
|---|---|---|
| ABCD | Experimental | Control, Placebo, Caffeine, WBV Receives: Drug: Caffeine (300mg); Device: whole-body vibration; Dietary Supplement: Placebo; Behavioral: Control |
| BCDA | Experimental | Placebo, Caffeine, WBV, Control Receives: Drug: Caffeine (300mg); Device: whole-body vibration; Dietary Supplement: Placebo; Behavioral: Control |
| CDAB | Experimental | Caffeine, WBV, Control, Placebo Receives: Drug: Caffeine (300mg); Device: whole-body vibration; Dietary Supplement: Placebo; Behavioral: Control |
| DABC | Experimental | WBV, Control, Placebo, Caffeine Receives: Drug: Caffeine (300mg); Device: whole-body vibration; Dietary Supplement: Placebo; Behavioral: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bench press and back squat Peak VELOCITY
Highest velocity of production
Measured: around 4 weeks from the 1st to the last session
Peak Torque MVC
Highest torque exerted during trial
Measured: around 4 weeks from the 1st to the last session
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Mar 2027 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vibration TherapyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Liverpool John Moores University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joao Pedro Saes Agulhari, Liverpool John Moores University
- Investigators
- Joao PS Agulhari, BSc, Principal investigator, Liverpool John Moores University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07921810
- Sponsor's protocol ID
- 261015LJMUSPSREC347
- Status last verified
- Nov 2026
- First submitted
- 29 Oct 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Morning Strength and Cognitive Performance Using Caffeine or Whole-body Vibration.
- ClinicalTrials.gov ID
- NCT07921810
- Acronym / sponsor ID
- 261015LJMUSPSREC347
- Conditions
- Vibration Therapy, Caffeine, Control Condition, Placebo - Control
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Liverpool John Moores UniversityUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 1 Mar 2027 (estimated)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Improving morning strength and cognitive performance using caffeine or whole-body vibration.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| ABCD | Experimental | Drug: Caffeine (300mg), Device: whole-body vibration, Dietary Supplement: Placebo, Behavioral: ControlControl, Placebo, Caffeine, WBV |
| BCDA | Experimental | Drug: Caffeine (300mg), Device: whole-body vibration, Dietary Supplement: Placebo, Behavioral: ControlPlacebo, Caffeine, WBV, Control |
| CDAB | Experimental | Drug: Caffeine (300mg), Device: whole-body vibration, Dietary Supplement: Placebo, Behavioral: ControlCaffeine, WBV, Control, Placebo |
| DABC | Experimental | Drug: Caffeine (300mg), Device: whole-body vibration, Dietary Supplement: Placebo, Behavioral: ControlWBV, Control, Placebo, Caffeine |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age: 18-35years old
- Healthy (as determined by the pre-participation questionnaire)
- >2 years strength trained individuals
- Consume >150 mg/day of caffeine
- Be able to stick to the retiring and waking schedule of the study as well as no exercise 24 h before and no caffeine.
Key exclusion criteria (5 listed)
- Age: <18 or >35 years old
- Consume <150 mg/day of caffeine
- Deemed unhealthy/unable to perform exercise determined by PAR-Q
- Shift worker or having travelled out of the UK time zone within the last month of testing
- Muscle related injury or broken/fractured bone within the past 3 years Diagnosed sleep disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Caffeine (300mg)Caffeine (300mg; 3x 100mg) | Drug | ABCD, BCDA, CDAB, DABC |
| whole-body vibration15 min of WBV at 60 Hz | Device | ABCD, BCDA, CDAB, DABC |
| Placebo1.6 mg Maltodextrin | Dietary supplement | ABCD, BCDA, CDAB, DABC |
| Controlno-pill control | Behavioural | ABCD, BCDA, CDAB, DABC |
Primary outcome
Bench press and back squat Peak VELOCITY
Time frame: around 4 weeks from the 1st to the last session
Highest velocity of production
Peak Torque MVC
Time frame: around 4 weeks from the 1st to the last session
Highest torque exerted during trial
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Vibration Therapy
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Not yet recruiting
Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response
Hepatocellular Carcinoma, Liver Cancer
Active, not recruiting
rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression
Depression, Treatment Resistant
RecruitingPhase 2
Spironolactone for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Recruiting
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joao PS Agulhari, BSc principal investigator
Liverpool John Moores University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Caffeine (300mg) and whole-body vibration in people with Vibration Therapy and Caffeine, run by Liverpool John Moores University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joao Agulhari, BSc (07379664724, jpagulhari@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bench press and back squat Peak VELOCITY (time frame: around 4 weeks from the 1st to the last session). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.